Blog

Evidence-First Supplement Prioritization

Unfair Team • February 5, 2026

The supplement market runs on enthusiasm. Someone posts a transformation story, a podcast host recommends a new compound, and suddenly everyone is buying it. The problem is not that these supplements never work. The problem is that you have limited time, money, and experimental bandwidth, and spending it on a compound with three rat studies and a Reddit thread means you are not spending it on something with twenty human trials and an effect size you can detect in your own data.

Evidence-first prioritization is a decision rule: start with the best-supported compounds. Only move down the evidence ladder after you have exhausted (or ruled out) the options at the top.

The evidence tiers

Not all evidence is equal. Knowing where a supplement sits on this ladder tells you how much confidence to place in it before you run your own trial.

How to use the tiers

The rule is simple: do not move to Tier 2 until you have tested or ruled out the Tier 1 options for your goal. Do not move to Tier 3 until Tier 2 has been explored.

This is not because Tier 2 and 3 supplements never work. Some of them do, for some people. But your time and attention are finite. Starting with the highest-probability options maximizes the chance that your first experiment produces a signal you can act on.

Worked example: Prioritizing for sleep improvement

Suppose your goal is reducing sleep onset latency (falling asleep faster).

Step 1: Identify candidates by tier.

Notice there is no Tier 1 option for sleep onset. That is fine. It means you start with the best Tier 2 option for your situation.

Step 2: Choose one candidate based on your context.

If your circadian rhythm is shifted (you are a "night owl" who wants to sleep earlier), melatonin is the better first choice because it addresses timing. If your sleep environment and schedule are stable but you suspect low magnesium intake, magnesium is a reasonable first test.

Step 3: Run a structured trial.

Pick one. Test it for the appropriate duration (7-14 nights for melatonin, 3-6 weeks for magnesium). Log sleep onset latency nightly. Compare to your baseline average. Decide keep, adjust, or remove based on the pre-set threshold you defined before starting. ¹²

Step 4: If the first candidate fails, move to the next.

A null result is not wasted time. It eliminates an option and narrows your search. Return to baseline for a week, then test the next candidate on the list.

How to read evidence without a science degree

You do not need to read full papers to prioritize effectively. Here is what to look for:

Systematic reviews and meta-analyses pool results from multiple studies. If a meta-analysis of 10+ trials shows a consistent positive effect, that is more reliable than any single trial, no matter how impressive the single trial looks.

Position stands from professional organizations (like the International Society of Sports Nutrition or the American College of Gastroenterology) synthesize evidence and make practical recommendations. These are written for practitioners and are usually the most actionable source.

The NIH Office of Dietary Supplements (ODS) fact sheets provide balanced, regularly updated summaries of evidence for individual supplements. They note where evidence is strong, where it is mixed, and where safety concerns exist.

What to watch out for:

• Single studies with dramatic results. One study is a data point, not a conclusion. Look for replication.
• Industry-funded studies without independent replication. Not automatically invalid, but treat with appropriate caution.
• Studies in populations that do not match you. A trial in elderly hospitalized patients may not predict what happens in a healthy 30-year-old.
• Dose mismatch. If the study used 600mg and the product contains 100mg, the study does not support the product.

Common prioritization mistakes

Skipping Tier 1 because it is "boring." Creatine, protein, and caffeine are not exciting. They are also the most robustly supported performance supplements available. ^{1 2 4} Novelty is not a prioritization criterion.

Treating all positive studies as equal. A 12-person pilot study and a 500-person meta-analysis are not equivalent evidence. Weight your decisions accordingly.

Ignoring null results. When a well-designed trial shows no effect, that is informative. It means the compound probably does not do what you hoped, at least at that dose for that population. Do not dismiss nulls because they are disappointing.

Confusing "evidence of absence" with "absence of evidence." A Tier 3 supplement may work. It just has not been tested well enough to know. That uncertainty is the reason to deprioritize it, not to dismiss it forever.

Evidence-first prioritization in Unfair

Unfair's recommendation engine ranks supplement candidates by evidence strength for your stated goal. Tier 1 options are presented first, with links to the supporting evidence. Tier 2 options are available but labeled as having more variable evidence. Tier 3 options are deprioritized unless you specifically request them. Your personal trial results are layered on top, so over time your rankings reflect both population-level evidence and your individual response data.

Continue with Top 10 Supplement Myths Debunked, Common Supplement Stack Mistakes to Avoid, and Evaluating AI Supplement Recommendations.

References